Home » Drug Shows Positive Responses, Low Side Effects in Multiple Myeloma
Drug Shows Positive Responses, Low Side Effects in Multiple Myeloma
The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple
myeloma patients in a phase II clinical trial, researchers reported Monday at the 51st Annual Meeting of the American Society of Hematology.
PhysOrg
PhysOrg
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May